From a University Spin-Out to a Global Company
Pacific GeneTech develops and commercializes first-in-class or best-in-class vaccines for areas of high unmet or underserved needs in food safety and animal health. The global animal vaccine market is a valuable opportunity growing at an annual rate of 6% and is expected to reach US$13.4 billion by 2026. Infectious diseases in animals cause significant economic loss to meat producers and also result in human infections. Increasingly, “zoonotic” diseases common to animals and humans are recognized as a part of the “One Health” concept, a worldwide strategy for expanding interdisciplinary collaborations in all aspects of health care for humans, animals and the environment. Pacific GeneTech’s technologies and business philosophy are fully aligned to One Health.
Founded in 2009, Pacific GeneTech was formed to globally commercialize a next-generation animal vaccine platform that was developed by a consortium of leading US universities, and partially funded by the US government. Our proprietary Aegis vaccine platform is the basis for developing new first-in-class or best-in-class recombinant vaccines that provide broad protection against multiple strains and species of pathogens. Since acquiring the rights to Aegis, initially created for veterinary applications, we are expanding beyond our first poultry vaccines into pigs, ruminants (cows and sheep) and companion animals, and we have early stage human programs in place for related diseases, specifically gastro-intestinal bacteria causing dysenteric disease and Plasmodium vivax, the parasite causing recurrent malaria. It is estimated that bacterial dysenteric diseases (ETEC, nontyphoidal Salmonella) cause over half a million deaths per annum, particularly among children. As for Plasmodium vivax malaria, 2.5 billion people are at risk of infection and, unlike the more deadly Plasmodium falciparum, it is found well beyond tropical regions, including in Europe. There is no vaccine available for Plasmodium vivax. Pacific GeneTech’s subsidiary, PGTx, is dedicated to the development of human vaccines.
In addition to the original discovery institutions, we have developed research collaborations with other leading institutions around the world for the development of our Aegis vaccines and Hercules adjuvant, and acquired other leading-edge vaccine technologies. In 2020, PGT acquired the rights to a novel DNA vaccine candidate for African Swine Fever (ASF). PGT is in the process of working with development partners in key ASF affected areas of the world to develop and commercialize this vaccine.